Preventing intestinal disease with oxygen
Clinically validated efficacy
Novel oral administration
Addressing an urgent public health threat
We are focused on the prevention of antibiotic-induced C. difficile colitis infections, a leading cause of healthcare-associated infections.
No vaccine hesitancy
No stewardship restrictions
Targeted prevention without systemic disruption.
The LPOXY team is driven to protect people from this deadly antibiotic-induced superinfection
• The Centers for Disease Control and Prevention considers C. difficile colitis an URGENT public health threat.
• C. difficile colitis afflicts nearly a half million Americans each year.
• 30,000 will die.
• There are no therapies or vaccines to prevent this antibiotic-induced superinfection.
LPOXY Therapeutics is developing a pill that taken with antibiotics gently increases the colon’s oxygen tension to prevent antibiotic-induced C. difficile colitis via multiple mechanisms.
Watch a video about antibiotics and C. difficile colitis here.
SIDIPREV™ orally-administered, metered-dose intestinal oxygen delivery is being developed for multiple indications
-
Antibiotic-induced C. difficile colitis superinfection prevention
Oxygen’s clinical effectiveness established in humans
-
Inflammatory Bowel Diseases: Crohn's & Ulcerative Colitis
Oxygen’s clinical effectiveness established in humans
